Stay updated with the latest EU regulations and guidance in the medical device industry. Check out our comprehensive summary of key updates including new standards, legislative acts, and guidance documents. Dive in now to stay compliant and informed!
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202400815
The Implementing Decision amended the list of harmonized standards in Europe under MDR with the following:
- EN 455-3:2023: Medical gloves for single use – Requirements and testing for biological evaluation.
- EN ISO 10993-15:2023: Biological evaluation of medical devices – Identification and quantification of degradation products from metals and alloys.
- EN ISO 10993-17:2023: Biological evaluation of medical devices – Toxicological risk assessment of medical device constituents.
- EN ISO 10993-18:2020/A1:2023: Biological evaluation of medical devices – Chemical characterization of medical device materials within a risk management process.
- EN ISO 11137-2:2015/A1:2023: Sterilization of health care products – Radiation – Establishing the sterilization dose.
- EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023: Packaging for terminally sterilized medical devices – Requirements for materials, sterile barrier systems, packaging systems, and validation requirements for forming, sealing, and assembly processes.
- EN ISO 17664-2:2023: Processing of health care products – Information provided by the medical device manufacturer for processing non-critical medical devices.
The consolidated list of MDR harmonized standards can be found at the following link: https://ec.europa.eu/docsroom/documents/58477/attachments/1/translations/en/renditions/native
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202400817
The Implementing Decision amended the list of harmonized standards in Europe under IVDR with the following:
- EN ISO 11137-2:2015/A1:2023: Sterilization of health care products – Radiation – Establishing the sterilization dose.
- EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023: Packaging for terminally sterilized medical devices – Requirements for materials, sterile barrier systems, packaging systems, and validation requirements for forming, sealing, and assembly processes.
The consolidated list of IVDR harmonized standards can be found at the following link: https://ec.europa.eu/docsroom/documents/58475/attachments/1/translations/en/renditions/native
The MDCG guidance document describes the Clinical Investigation Plan (CIP) for clinical investigations of medical devices. This guidance is pivotal for ensuring that clinical investigations are designed based on the latest scientific and technical insights, aiming to confirm the manufacturer's claims about a device's safety, performance, and benefit-risk profile. The document breaks down the essential elements of the CIP, starting from a general introduction that includes the investigation's title, objectives, and considering important requirements such as design of the clinical investigation, statistical analysis, data management, informed consent handling of adverse events, modifications of the CIP, etc., as well as a template of CIP synopsis. The document provides an exhaustive roadmap for sponsors to develop their own CIPs, facilitating the assessments by competent authorities and ethics committee and ensuring the compliance to MDR (especially Annex XV) and ISO14155:2020.
https://www.europarl.europa.eu/doceo/document/TA-9-2024-0138_EN.pdf
The legislation is currently undergoing a final review by legal and linguistic experts and is anticipated to be officially approved before the legislative session concludes. Additionally, a formal ratification by the Council is required and the regulation will become effective 20 days following its publication in the Official Journal.
The AI Act will take effect gradually up to 36 months later. The transition to full applicability of the AI Act involves a phased approach, balancing immediate safety and rights protections with longer-term regulatory adjustments for emerging technologies. High-risk AI systems are subjected to rigorous requirements from the outset, including accurate data use, risk assessment, and transparency. Prohibited practices, such as exploitative use of vulnerabilities and indiscriminate social scoring, are immediately enforceable to protect individuals' rights and societal values. The gradual enforcement allows stakeholders to adapt to new regulations, ensuring AI developments align with EU standards of safety, ethical use, and fundamental rights protection.
The AI Act, as adopted by the European Parliament, introduces a comprehensive framework for the regulation of AI within the EU, aiming to harmonize rules on AI development, deployment, and usage while ensuring safety, fundamental rights, and environmental protection. It categorizes AI systems based on risk, emphasizing stringent requirements for high-risk AI, including transparency, data governance, and human oversight. Prohibited practices include manipulative techniques, social scoring, and unauthorized use of biometric identification.
The EMA has released crucial instructions for Notified Bodies concerning the application of Articles 54 (MDR) / 48 (IVDR) on the Clinical/Performance Consultation Procedure.
Manufacturers of Class III implantable devices and Class IIb active devices intended to administer and/or remove a medicinal product (unless specific exemption criteria are fulfilled (MDR Article 54(2))) as well as for first certification of Class D devices where no Common Specifications (CS) are available, the NBs are required to consult the expert panel to obtain a scientific opinion.
These procedures involve a step-by-step workflow for Notified Bodies, starting from determining if a device qualifies for consultation, through the uploading of relevant documentation onto the CIRCABC platform, to the consideration of expert panel opinions in the conformity assessment. The instructions detail the documents required, the marking of sensitive information, and the responsibilities of the Secretariat in managing the consultation process. The guidance aims to ensure the efficient and secure transmission of documents, while also outlining the publication of expert panel opinions and the handling of commercially confidential information.
- Update of the MDCG 2019-9 - Rev.1 Summary of safety and clinical performance
- Guidance on content of Investigator’s Brochure for clinical investigations conducted under (EU) regulation 2017/745
- Update MIR form
- Guidance on Post-Market Surveillance
- MDR Vigilance guidance on implementation of Articles 87 to 90 MDR
- Revision of Trend report and related documents
- Update of Field Safety Corrective Action form
- Extension of PSUR guidance for IVDR
- Notified Body Technical Documentation Assessment Report
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.